share_log

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Monte Rosa Therapeutics將在第43屆摩根大通醫療健康會議上發言
GlobeNewswire ·  01/06 12:00

BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 5:15 p.m. PST.

波士頓,2025年1月6日(環球新聞通訊社) -- 蒙特羅莎治療公司。 (納斯達克:GLUE),一家臨牀階段的生物技術公司,正在開發基於新型分子粘合降解劑(MGD)的藥物,今天宣佈首席執行官Markus Warmuth萬.D.將於2025年1月14日星期二下午5:15(太平洋時間)在第43屆摩根大通醫療健康會議上進行演講。

A webcast of the presentation will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.

演講的網絡廣播將可通過Monte Rosa官方網站的 "活動與演示 "部分訪問,網址爲ir.monterosatx.com,演講後的30天內將提供存檔版本。

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa's QuEEN (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry's leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit .

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa's QuEEN (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry's leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit .

Investors
Andrew Funderburk
ir@monterosatx.com

投資者
安德魯·芬德伯克
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

媒體
科裏·湯布利,科學公關
media@monterosatx.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 390

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。